September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark.1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents.
BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the Netherlands, and Luxembourg with Rutherford 2-5 disease and at least two centimeters of healthy vessel segment between lesions in the popliteal artery and lesions in the distal superficial femoral artery. All patients were treated with the Passeo-18 Lux DCB. The bail-out stenting rate was 14%.
At 24 months:
- Freedom from clinically driven target lesion revascularization (CD-TLR)2 was 81.6%
- Freedom from major target limb amputation was 98.0%
- Freedom from all-cause of death was 89.4%
- Significant improvement of Rutherford classification was observed for 88.1% of the patients
"We face a scarcity of data evaluating endovascular therapy for isolated popliteal artery lesions, known as a difficult vessel bed to treat as we don’t want to leave anything behind," said Principal Investigator Prof. Frank Vermassen, Chief of Vascular and Thoracic Surgery at UZ Ghent in Ghent, Belgium. "It is encouraging to see that we can safely and effectively treat these lesions with a DCB-only approach."
"BIOTRONIK is proud to be a leader in research of paclitaxel-coated balloons, striving to study device performance in the most challenging anatomy and patient characteristics," said Stuart Perks, Vice President of Marketing, Vascular Intervention at BIOTRONIK. "We repeatedly see the safety and effectiveness of Passeo-18 Lux DCB demonstrated in a diverse range of clinical presentations."
For more information: www.biotronik.com
References:
1 Vermassen F. A prospective, international, multi-centre, post-market all-comers registry to assess the clinical performance of the Passeo-18 Lux DCB in isolated popliteal arteries – BIOLUX P-III BENELUX. Presented at: CIRSE 2023; September 9-13, 2023; Copenhagen, Denmark.
2 CD-TLR is defined as any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.
Passeo and Lux are trademarks or registered trademarks of the BIOTRONIK Group of Companies.
Passeo-18 Lux paclitaxel-releasing PTA balloon catheter is not available for sale or use in the United States.
Related Content:
BIOPACT RCT Subgroup Analyses Show Consistently Great Results for Passeo-18 Lux Drug-Coated Balloon
July 27, 2023 
